<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01078558</url>
  </required_header>
  <id_info>
    <org_study_id>HUM04-28</org_study_id>
    <nct_id>NCT01078558</nct_id>
  </id_info>
  <brief_title>A Belgian Registry of HUMIRAÂ® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )</brief_title>
  <acronym>ProAct</acronym>
  <official_title>A Five Year, Post-marketing Observational Study to Follow-up Patients With Rheumatoid Arthritis or Psoriatic Arthritis Who Are Treated With HUMIRA (Adalimumab)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veeda Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a five year, post-marketing observational study to follow-up patients with rheumatoid
      arthritis, psoriatic arthritis or ankylosing spondylitis who are treated with HUMIRA
      (adalimumab).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 13, 2004</start_date>
  <completion_date type="Actual">January 11, 2018</completion_date>
  <primary_completion_date type="Actual">January 11, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Physician's Assessment of Disease Activity Over Time</measure>
    <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
    <description>Physician's assessment of disease activity is measured on a visual analogue scale (VAS) from 0 to 100, with the highest values indicating the worst disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Tender Joints Over Time</measure>
    <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
    <description>A total of 28 joints were assessed for tenderness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Swollen Joints Over Time</measure>
    <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
    <description>A total of 28 joints were assessed for swelling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory Parameter: Change From Baseline in CRP Over Time</measure>
    <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory Parameter: Change From Baseline in ESR Over Time</measure>
    <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Function: Change From Baseline in HAQ% Over Time</measure>
    <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
    <description>The HAQ score measures quality of life in terms of physical function and consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past 7 days using the following responses: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). In the classical HAQ questionnaire, the potential maximum score (60) indicates the most severe disability and the minimum score (0) indicates no disability. The HAQ% is a typical 'Belgian scoring method,' where the actual total score on 60 is converted to a percentage. The HAQ% is performed by all Belgian rheumatologists and is required for obtaining reimbursement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in DAS28 Over Time: RA Participants</measure>
    <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
    <description>The DAS28 score includes 28 tender joint counts, 28 swollen joint counts, CRP/ESR, and participant's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DAS28 Category Over Time: RA Participants</measure>
    <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
    <description>The DAS28 score includes 28 tender joint counts, 28 swollen joint counts, CRP/ESR, and participant's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BSA With PsA Over Time: PsA Participants</measure>
    <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Patient's Numerical Rating Scale Over Time: Oligoarticular PsA Participants</measure>
    <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
    <description>Participants used a Numerical Rating Scale of 0 to 10 to assess the most important joint, where 0=no disease activity during the previous days and 10=maximal activity during the previous days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Physician's Numerical Rating Scale Over Time: Oligoarticular PsA Participants</measure>
    <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
    <description>Physicians used a Numerical Rating Scale of 0 to 10 to assess the most important joint, where 0=no disease activity during the previous days and 10=maximal activity during the previous days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in BASDAI Over Time: AS Participants</measure>
    <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
    <description>BASDAI score measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness, and is calculated using a questionnaire with 6 questions that the participant completes by marking answers on a 10-centimeter visual analog scale with responses that range from 0 (none) to 10 (very severe). The final BASDAI score ranges from 0 to 10 with higher score indicating more severe symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) Serious AEs (SAEs), and AEs Leading to Study Drug Discontinuation</measure>
    <time_frame>up to 60 months</time_frame>
    <description>An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. An SAE is an AE that results in death, is life-threatening, results in or prolongs hospitalization, results in congenital anomaly, persistent or significant disability/incapacity, spontaneous or elective abortion, or requires intervention to prevent a serious outcome. The protocol required all SAEs to be actively solicited. Non-serious events were not to be actively solicited, and any non-serious AEs were to be collected as spontaneous reports if AbbVie was notified.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5940</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Patients with rheumatic disease</arm_group_label>
    <description>Patients suffering from rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Rheumatologists
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ongoing HUMIRA (adalimumab) treatment who have been prescribed HUMIRA
             (adalimumab) within local reimbursement guidelines.

          -  Patients must be willing to consent to data being collected and provided to Abbott
             Laboratories.

        Exclusion Criteria:

          -  Contraindications according to the summary of product characteristics.

          -  Patients who are actually followed in the ReAlise registry (M03-634 NCT00234884).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Luxembourg</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <results_first_submitted>January 9, 2019</results_first_submitted>
  <results_first_submitted_qc>April 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2019</results_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multicenter study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 16, 2006</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT01078558/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT01078558/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 5940 participants (2845 with rheumatoid arthritis [RA], 1128 with psoriatic arthritis [PsA], and 1967 with ankylosing spondylitis [AS]) were enrolled. Twenty of these participants were younger than 18 years old (9 RA participants, 1 PsA participant, and 10 AS participants); these participants were not included in any analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Participants With RA</title>
          <description>Participants diagnosed with RA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
        </group>
        <group group_id="P2">
          <title>Participants With PsA</title>
          <description>Participants diagnosed with PsA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
        </group>
        <group group_id="P3">
          <title>Participants With AS</title>
          <description>Participants diagnosed with AS in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2836"/>
                <participants group_id="P2" count="1127"/>
                <participants group_id="P3" count="1957"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Oligoarticular PsA</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="197"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="818"/>
                <participants group_id="P2" count="372"/>
                <participants group_id="P3" count="596"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2018"/>
                <participants group_id="P2" count="755"/>
                <participants group_id="P3" count="1361"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Participants With RA</title>
          <description>Participants diagnosed with RA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
        </group>
        <group group_id="B2">
          <title>Participants With PsA</title>
          <description>Participants diagnosed with PsA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
        </group>
        <group group_id="B3">
          <title>Participants With AS</title>
          <description>Participants diagnosed with AS in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2836"/>
            <count group_id="B2" value="1127"/>
            <count group_id="B3" value="1957"/>
            <count group_id="B4" value="5920"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>1 participant in the AS arm had missing data.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2836"/>
                    <count group_id="B2" value="1127"/>
                    <count group_id="B3" value="1956"/>
                    <count group_id="B4" value="5919"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.64" spread="12.96"/>
                    <measurement group_id="B2" value="49.52" spread="12.36"/>
                    <measurement group_id="B3" value="43.62" spread="12.47"/>
                    <measurement group_id="B4" value="50.98" spread="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2836"/>
                    <count group_id="B2" value="1127"/>
                    <count group_id="B3" value="1957"/>
                    <count group_id="B4" value="5920"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2004"/>
                    <measurement group_id="B2" value="523"/>
                    <measurement group_id="B3" value="903"/>
                    <measurement group_id="B4" value="3430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2836"/>
                    <count group_id="B2" value="1127"/>
                    <count group_id="B3" value="1957"/>
                    <count group_id="B4" value="5920"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="787"/>
                    <measurement group_id="B2" value="591"/>
                    <measurement group_id="B3" value="1033"/>
                    <measurement group_id="B4" value="2411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2836"/>
                    <count group_id="B2" value="1127"/>
                    <count group_id="B3" value="1957"/>
                    <count group_id="B4" value="5920"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician's Assessment of Disease Activity</title>
          <description>Physician's assessment of disease activity is measured on a visual analogue scale (VAS) from 0 to 100, with the highest values indicating the worst disease activity.</description>
          <population>Includes all participants with a Baseline assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2579"/>
                    <count group_id="B2" value="1026"/>
                    <count group_id="B3" value="1741"/>
                    <count group_id="B4" value="5346"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.47" spread="22.93"/>
                    <measurement group_id="B2" value="54.58" spread="22.59"/>
                    <measurement group_id="B3" value="59.21" spread="25.32"/>
                    <measurement group_id="B4" value="57.96" spread="23.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender Joints</title>
          <description>A total of 28 joints were assessed for tenderness.</description>
          <population>Includes all participants with a Baseline assessment.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2664"/>
                    <count group_id="B2" value="1046"/>
                    <count group_id="B3" value="959"/>
                    <count group_id="B4" value="4669"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.73" spread="8.90"/>
                    <measurement group_id="B2" value="10.47" spread="8.34"/>
                    <measurement group_id="B3" value="2.40" spread="4.31"/>
                    <measurement group_id="B4" value="10.67" spread="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joints</title>
          <description>A total of 28 joints were assessed for swelling.</description>
          <population>Includes all participants with a Baseline assessment.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2719"/>
                    <count group_id="B2" value="1049"/>
                    <count group_id="B3" value="940"/>
                    <count group_id="B4" value="4708"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.79" spread="7.18"/>
                    <measurement group_id="B2" value="7.46" spread="5.37"/>
                    <measurement group_id="B3" value="1.44" spread="3.21"/>
                    <measurement group_id="B4" value="8.18" spread="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Inflammatory Parameter: C-Reactive Protein (CRP)</title>
          <population>Includes all participants with a Baseline assessment.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2437"/>
                    <count group_id="B2" value="937"/>
                    <count group_id="B3" value="1528"/>
                    <count group_id="B4" value="4902"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.68" spread="8.44"/>
                    <measurement group_id="B2" value="2.53" spread="6.90"/>
                    <measurement group_id="B3" value="3.24" spread="19.11"/>
                    <measurement group_id="B4" value="3.32" spread="12.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Inflammatory Parameter: Erythrocyte Sedimentation Rate (ESR)</title>
          <population>Includes all participants with a Baseline assessment.</population>
          <units>mm/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2320"/>
                    <count group_id="B2" value="836"/>
                    <count group_id="B3" value="1257"/>
                    <count group_id="B4" value="4413"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.58" spread="21.84"/>
                    <measurement group_id="B2" value="18.87" spread="18.45"/>
                    <measurement group_id="B3" value="21.09" spread="19.23"/>
                    <measurement group_id="B4" value="24.08" spread="20.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Assessment Questionnaire (HAQ%)</title>
          <description>The HAQ score measures quality of life in terms of physical function and consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. In the classical HAQ questionnaire, the potential maximum score (60) indicates the most severe disability and the minimum score (0) indicates no disability. The HAQ% is a typical âBelgian scoring method,' where the actual total score on 60 is converted to a percentage. The HAQ% is performed by all Belgian rheumatologists and is required for obtaining reimbursement.</description>
          <population>Includes all participants with a Baseline assessment.</population>
          <units>percentage of maximum HAQ score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2555"/>
                    <count group_id="B2" value="845"/>
                    <count group_id="B3" value="69"/>
                    <count group_id="B4" value="3469"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.80" spread="19.22"/>
                    <measurement group_id="B2" value="41.01" spread="18.65"/>
                    <measurement group_id="B3" value="40.80" spread="24.57"/>
                    <measurement group_id="B4" value="46.00" spread="19.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Activity Score for 28 Joints (DAS28): RA Participants</title>
          <description>The DAS28 score includes 28 tender joint counts, 28 swollen joint counts, CRP/ESR, and participant's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>Includes all RA participants with a Baseline assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="383"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.04" spread="1.21"/>
                    <measurement group_id="B4" value="5.04" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DAS28 Category</title>
          <description>The DAS28 score includes 28 tender joint counts, 28 swollen joint counts, CRP/ESR, and participant's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>Includes all RA participants with a Baseline assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 2.6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="383"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â¥ 2.6 to â¤ 3.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="383"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 3.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="383"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="383"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="363"/>
                    <measurement group_id="B4" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area (BSA) with PsA</title>
          <population>Includes all PsA participants with a Baseline assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 3% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="783"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="783"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="353"/>
                    <measurement group_id="B4" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3% to 10% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="783"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="783"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B4" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11% to 20% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="783"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="783"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 20% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="783"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="783"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient's Numerical Rating Scale for Oligarticular PsA Participants</title>
          <description>Participants used a Numerical Rating Scale of 0 to 10 to assess the most important joint, where 0=no disease activity during the previous days and 10=maximal activity during the previous days.</description>
          <population>Includes all oligoarticular PsA participants with a Baseline assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="94"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="6.6" spread="2.0"/>
                    <measurement group_id="B4" value="6.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician's Numerical Rating Scale for Oligoarticular PsA Participants</title>
          <description>Physicians used a Numerical Rating Scale of 0 to 10 to assess the most important joint, where 0=no disease activity during the previous days and 10=maximal activity during the previous days.</description>
          <population>Includes all oligoarticular PsA participants with a Baseline assessment by the physican.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="95"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="6.2" spread="2.0"/>
                    <measurement group_id="B4" value="6.2" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for AS Participants</title>
          <description>BASDAI score measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness, and is calculated using a questionnaire with 6 questions that the participant completes by marking answers on a 10-centimeter visual analog scale with responses that range from 0 (none) to 10 (very severe). The final BASDAI score ranges from 0 to 10 with higher score indicating more severe symptoms.</description>
          <population>Includes all AS participants with a Baseline assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="1698"/>
                    <count group_id="B4" value="1698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="6.2" spread="1.9"/>
                    <measurement group_id="B4" value="6.2" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Physician's Assessment of Disease Activity Over Time</title>
        <description>Physician's assessment of disease activity is measured on a visual analogue scale (VAS) from 0 to 100, with the highest values indicating the worst disease activity.</description>
        <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
        <population>All participants with a Baseline and post-baseline assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With RA</title>
            <description>Participants diagnosed with RA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Participants With PsA</title>
            <description>Participants diagnosed with PsA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Participants With AS</title>
            <description>Participants diagnosed with AS in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Assessment of Disease Activity Over Time</title>
          <description>Physician's assessment of disease activity is measured on a visual analogue scale (VAS) from 0 to 100, with the highest values indicating the worst disease activity.</description>
          <population>All participants with a Baseline and post-baseline assessment at given time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1781"/>
                <count group_id="O2" value="687"/>
                <count group_id="O3" value="1232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1781"/>
                    <count group_id="O2" value="687"/>
                    <count group_id="O3" value="1232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.4" spread="24.7"/>
                    <measurement group_id="O2" value="-36.2" spread="24.8"/>
                    <measurement group_id="O3" value="-40.2" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1682"/>
                    <count group_id="O2" value="645"/>
                    <count group_id="O3" value="1036"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.6" spread="26.4"/>
                    <measurement group_id="O2" value="-40.2" spread="25.6"/>
                    <measurement group_id="O3" value="-44.5" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1453"/>
                    <count group_id="O2" value="568"/>
                    <count group_id="O3" value="974"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.4" spread="27.2"/>
                    <measurement group_id="O2" value="-43.2" spread="26.6"/>
                    <measurement group_id="O3" value="-46.6" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1178"/>
                    <count group_id="O2" value="450"/>
                    <count group_id="O3" value="771"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.4" spread="26.9"/>
                    <measurement group_id="O2" value="-42.2" spread="27.2"/>
                    <measurement group_id="O3" value="-46.6" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="565"/>
                    <count group_id="O2" value="243"/>
                    <count group_id="O3" value="399"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.2" spread="27.3"/>
                    <measurement group_id="O2" value="-44.8" spread="29.3"/>
                    <measurement group_id="O3" value="-50.2" spread="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Tender Joints Over Time</title>
        <description>A total of 28 joints were assessed for tenderness.</description>
        <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
        <population>All participants with a Baseline and post-baseline assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With RA</title>
            <description>Participants diagnosed with RA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Participants With PsA</title>
            <description>Participants diagnosed with PsA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Participants With AS</title>
            <description>Participants diagnosed with AS in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tender Joints Over Time</title>
          <description>A total of 28 joints were assessed for tenderness.</description>
          <population>All participants with a Baseline and post-baseline assessment at given time point.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1959"/>
                <count group_id="O2" value="755"/>
                <count group_id="O3" value="634"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1959"/>
                    <count group_id="O2" value="755"/>
                    <count group_id="O3" value="634"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="8.0"/>
                    <measurement group_id="O2" value="-6.8" spread="7.8"/>
                    <measurement group_id="O3" value="-1.6" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1862"/>
                    <count group_id="O2" value="706"/>
                    <count group_id="O3" value="533"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="8.6"/>
                    <measurement group_id="O2" value="-7.6" spread="7.6"/>
                    <measurement group_id="O3" value="-1.9" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1626"/>
                    <count group_id="O2" value="615"/>
                    <count group_id="O3" value="499"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="8.9"/>
                    <measurement group_id="O2" value="-8.0" spread="7.7"/>
                    <measurement group_id="O3" value="-1.9" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1298"/>
                    <count group_id="O2" value="513"/>
                    <count group_id="O3" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" spread="8.9"/>
                    <measurement group_id="O2" value="-7.9" spread="7.9"/>
                    <measurement group_id="O3" value="-2.0" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="637"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="202"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="8.2"/>
                    <measurement group_id="O2" value="-8.3" spread="8.7"/>
                    <measurement group_id="O3" value="-1.9" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Swollen Joints Over Time</title>
        <description>A total of 28 joints were assessed for swelling.</description>
        <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
        <population>All participants with a Baseline and post-baseline assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With RA</title>
            <description>Participants diagnosed with RA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Participants With PsA</title>
            <description>Participants diagnosed with PsA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Participants With AS</title>
            <description>Participants diagnosed with AS in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Swollen Joints Over Time</title>
          <description>A total of 28 joints were assessed for swelling.</description>
          <population>All participants with a Baseline and post-baseline assessment at given time point.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1982"/>
                <count group_id="O2" value="755"/>
                <count group_id="O3" value="623"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1982"/>
                    <count group_id="O2" value="755"/>
                    <count group_id="O3" value="623"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="6.7"/>
                    <measurement group_id="O2" value="-5.6" spread="5.7"/>
                    <measurement group_id="O3" value="-1.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1890"/>
                    <count group_id="O2" value="706"/>
                    <count group_id="O3" value="518"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="7.1"/>
                    <measurement group_id="O2" value="-6.1" spread="5.2"/>
                    <measurement group_id="O3" value="-1.4" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1654"/>
                    <count group_id="O2" value="619"/>
                    <count group_id="O3" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="7.3"/>
                    <measurement group_id="O2" value="-6.5" spread="5.4"/>
                    <measurement group_id="O3" value="-1.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1328"/>
                    <count group_id="O2" value="510"/>
                    <count group_id="O3" value="367"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="7.4"/>
                    <measurement group_id="O2" value="-6.5" spread="5.8"/>
                    <measurement group_id="O3" value="-1.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="638"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="6.7"/>
                    <measurement group_id="O2" value="-6.8" spread="6.4"/>
                    <measurement group_id="O3" value="-1.4" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inflammatory Parameter: Change From Baseline in CRP Over Time</title>
        <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
        <population>All participants with a Baseline and post-baseline assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With RA</title>
            <description>Participants diagnosed with RA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Participants With PsA</title>
            <description>Participants diagnosed with PsA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Participants With AS</title>
            <description>Participants diagnosed with AS in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Parameter: Change From Baseline in CRP Over Time</title>
          <population>All participants with a Baseline and post-baseline assessment at given time point.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1607"/>
                <count group_id="O2" value="568"/>
                <count group_id="O3" value="838"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1607"/>
                    <count group_id="O2" value="568"/>
                    <count group_id="O3" value="838"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="8.0"/>
                    <measurement group_id="O2" value="-1.6" spread="7.1"/>
                    <measurement group_id="O3" value="-2.8" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1510"/>
                    <count group_id="O2" value="531"/>
                    <count group_id="O3" value="707"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="6.7"/>
                    <measurement group_id="O2" value="-1.8" spread="9.0"/>
                    <measurement group_id="O3" value="-2.6" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1338"/>
                    <count group_id="O2" value="474"/>
                    <count group_id="O3" value="677"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="7.3"/>
                    <measurement group_id="O2" value="-1.6" spread="5.5"/>
                    <measurement group_id="O3" value="-2.7" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1103"/>
                    <count group_id="O2" value="408"/>
                    <count group_id="O3" value="580"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="7.0"/>
                    <measurement group_id="O2" value="-1.2" spread="9.0"/>
                    <measurement group_id="O3" value="-1.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="545"/>
                    <count group_id="O2" value="241"/>
                    <count group_id="O3" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="13.2"/>
                    <measurement group_id="O2" value="0.0" spread="13.8"/>
                    <measurement group_id="O3" value="-0.7" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inflammatory Parameter: Change From Baseline in ESR Over Time</title>
        <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
        <population>All participants with a Baseline and post-baseline assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With RA</title>
            <description>Participants diagnosed with RA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Participants With PsA</title>
            <description>Participants diagnosed with PsA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Participants With AS</title>
            <description>Participants diagnosed with AS in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Parameter: Change From Baseline in ESR Over Time</title>
          <population>All participants with a Baseline and post-baseline assessment at given time point.</population>
          <units>mm/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1478"/>
                <count group_id="O2" value="497"/>
                <count group_id="O3" value="670"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1478"/>
                    <count group_id="O2" value="497"/>
                    <count group_id="O3" value="670"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="18.3"/>
                    <measurement group_id="O2" value="-7.0" spread="17.6"/>
                    <measurement group_id="O3" value="-11.7" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1428"/>
                    <count group_id="O2" value="458"/>
                    <count group_id="O3" value="582"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="18.8"/>
                    <measurement group_id="O2" value="-8.1" spread="18.8"/>
                    <measurement group_id="O3" value="-10.5" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1234"/>
                    <count group_id="O2" value="402"/>
                    <count group_id="O3" value="536"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="19.4"/>
                    <measurement group_id="O2" value="-8.7" spread="18.0"/>
                    <measurement group_id="O3" value="-10.3" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1001"/>
                    <count group_id="O2" value="337"/>
                    <count group_id="O3" value="468"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="20.5"/>
                    <measurement group_id="O2" value="-6.2" spread="22.6"/>
                    <measurement group_id="O3" value="-8.6" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="468"/>
                    <count group_id="O2" value="190"/>
                    <count group_id="O3" value="235"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="19.9"/>
                    <measurement group_id="O2" value="-5.5" spread="17.4"/>
                    <measurement group_id="O3" value="-9.8" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physical Function: Change From Baseline in HAQ% Over Time</title>
        <description>The HAQ score measures quality of life in terms of physical function and consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past 7 days using the following responses: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). In the classical HAQ questionnaire, the potential maximum score (60) indicates the most severe disability and the minimum score (0) indicates no disability. The HAQ% is a typical 'Belgian scoring method,' where the actual total score on 60 is converted to a percentage. The HAQ% is performed by all Belgian rheumatologists and is required for obtaining reimbursement.</description>
        <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
        <population>All participants with a Baseline and post-baseline assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With RA</title>
            <description>Participants diagnosed with RA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Participants With PsA</title>
            <description>Participants diagnosed with PsA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Participants With AS</title>
            <description>Participants diagnosed with AS in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Function: Change From Baseline in HAQ% Over Time</title>
          <description>The HAQ score measures quality of life in terms of physical function and consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past 7 days using the following responses: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). In the classical HAQ questionnaire, the potential maximum score (60) indicates the most severe disability and the minimum score (0) indicates no disability. The HAQ% is a typical 'Belgian scoring method,' where the actual total score on 60 is converted to a percentage. The HAQ% is performed by all Belgian rheumatologists and is required for obtaining reimbursement.</description>
          <population>All participants with a Baseline and post-baseline assessment at given time point.</population>
          <units>percentage of maximum HAQ score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1580"/>
                <count group_id="O2" value="489"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1580"/>
                    <count group_id="O2" value="489"/>
                    <count group_id="O3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.4" spread="18.5"/>
                    <measurement group_id="O2" value="-19.1" spread="18.8"/>
                    <measurement group_id="O3" value="-19.6" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1568"/>
                    <count group_id="O2" value="479"/>
                    <count group_id="O3" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.9" spread="20.0"/>
                    <measurement group_id="O2" value="-23.2" spread="18.7"/>
                    <measurement group_id="O3" value="-25.8" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1279"/>
                    <count group_id="O2" value="374"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.7" spread="21.2"/>
                    <measurement group_id="O2" value="-24.5" spread="19.3"/>
                    <measurement group_id="O3" value="-33.4" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1064"/>
                    <count group_id="O2" value="320"/>
                    <count group_id="O3" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.4" spread="21.9"/>
                    <measurement group_id="O2" value="-24.5" spread="20.9"/>
                    <measurement group_id="O3" value="-32.3" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="524"/>
                    <count group_id="O2" value="165"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.4" spread="22.0"/>
                    <measurement group_id="O2" value="-27.1" spread="21.8"/>
                    <measurement group_id="O3" value="-34.9" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DAS28 Over Time: RA Participants</title>
        <description>The DAS28 score includes 28 tender joint counts, 28 swollen joint counts, CRP/ESR, and participant's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
        <population>All RA participants with a Baseline and post-baseline assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With RA</title>
            <description>Participants diagnosed with RA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28 Over Time: RA Participants</title>
          <description>The DAS28 score includes 28 tender joint counts, 28 swollen joint counts, CRP/ESR, and participant's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>All RA participants with a Baseline and post-baseline assessment at given time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.53" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>DAS28 Category Over Time: RA Participants</title>
        <description>The DAS28 score includes 28 tender joint counts, 28 swollen joint counts, CRP/ESR, and participant's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
        <population>All RA participants with a Baseline and post-baseline assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With RA</title>
            <description>Participants diagnosed with RA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>DAS28 Category Over Time: RA Participants</title>
          <description>The DAS28 score includes 28 tender joint counts, 28 swollen joint counts, CRP/ESR, and participant's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>All RA participants with a Baseline and post-baseline assessment at given time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 DAS28 &lt; 2.6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 DAS28 â¥ 2.6 to â¤ 3.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 DAS28 &lt; 3.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 DAS28 &lt; 2.6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 DAS28 â¥ 2.6 to â¤ 3.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 DAS28 &lt; 3.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 DAS28 &lt; 2.6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 DAS28 â¥ 2.6 to â¤ 3.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 DAS28 &lt; 3.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 DAS28 &lt; 2.6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 DAS28 â¥ 2.6 to â¤ 3.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 DAS28 &lt; 3.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 DAS28 &lt; 2.6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 DAS28 â¥ 2.6 to â¤ 3.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 DAS28 &lt; 3.2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>BSA With PsA Over Time: PsA Participants</title>
        <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
        <population>All PsA participants with a Baseline and post-baseline assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With RA</title>
            <description>Participants diagnosed with RA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>BSA With PsA Over Time: PsA Participants</title>
          <population>All PsA participants with a Baseline and post-baseline assessment at given time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3: &lt; 3% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="538"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: 3% to 10% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="538"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: 11% to 20% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="538"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: &gt; 20% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="538"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: &lt; 3% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="471"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: 3% to 10% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="471"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: 11% to 20% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="471"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: &gt; 20% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="471"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &lt; 3% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: 3% to 10% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: 11% to 20% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: &gt; 20% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24: &lt; 3% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24: 3% to 10% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24: 11% to 20% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24: &gt; 20% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60: &lt; 3% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60: 3% to 10% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60: 11% to 20% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60: &gt; 20% of BSA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Patient's Numerical Rating Scale Over Time: Oligoarticular PsA Participants</title>
        <description>Participants used a Numerical Rating Scale of 0 to 10 to assess the most important joint, where 0=no disease activity during the previous days and 10=maximal activity during the previous days.</description>
        <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
        <population>All oligoarticular PsA participants with a Baseline and post-baseline assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With PsA</title>
            <description>Participants diagnosed with PsA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient's Numerical Rating Scale Over Time: Oligoarticular PsA Participants</title>
          <description>Participants used a Numerical Rating Scale of 0 to 10 to assess the most important joint, where 0=no disease activity during the previous days and 10=maximal activity during the previous days.</description>
          <population>All oligoarticular PsA participants with a Baseline and post-baseline assessment at given time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Physician's Numerical Rating Scale Over Time: Oligoarticular PsA Participants</title>
        <description>Physicians used a Numerical Rating Scale of 0 to 10 to assess the most important joint, where 0=no disease activity during the previous days and 10=maximal activity during the previous days.</description>
        <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
        <population>All oligoarticular PsA participants with a Baseline and post-baseline assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With PsA</title>
            <description>Participants diagnosed with PsA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician's Numerical Rating Scale Over Time: Oligoarticular PsA Participants</title>
          <description>Physicians used a Numerical Rating Scale of 0 to 10 to assess the most important joint, where 0=no disease activity during the previous days and 10=maximal activity during the previous days.</description>
          <population>All oligoarticular PsA participants with a Baseline and post-baseline assessment at given time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in BASDAI Over Time: AS Participants</title>
        <description>BASDAI score measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness, and is calculated using a questionnaire with 6 questions that the participant completes by marking answers on a 10-centimeter visual analog scale with responses that range from 0 (none) to 10 (very severe). The final BASDAI score ranges from 0 to 10 with higher score indicating more severe symptoms.</description>
        <time_frame>Baseline, Months 3, 6, 12, 24, 60</time_frame>
        <population>All oligoarticular PsA participants with a Baseline and post-baseline assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With AS</title>
            <description>Participants diagnosed with AS in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BASDAI Over Time: AS Participants</title>
          <description>BASDAI score measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness, and is calculated using a questionnaire with 6 questions that the participant completes by marking answers on a 10-centimeter visual analog scale with responses that range from 0 (none) to 10 (very severe). The final BASDAI score ranges from 0 to 10 with higher score indicating more severe symptoms.</description>
          <population>All oligoarticular PsA participants with a Baseline and post-baseline assessment at given time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1011"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1011"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="821"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="775"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="621"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) Serious AEs (SAEs), and AEs Leading to Study Drug Discontinuation</title>
        <description>An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. An SAE is an AE that results in death, is life-threatening, results in or prolongs hospitalization, results in congenital anomaly, persistent or significant disability/incapacity, spontaneous or elective abortion, or requires intervention to prevent a serious outcome. The protocol required all SAEs to be actively solicited. Non-serious events were not to be actively solicited, and any non-serious AEs were to be collected as spontaneous reports if AbbVie was notified.</description>
        <time_frame>up to 60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants With RA</title>
            <description>Participants diagnosed with RA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Participants With PsA</title>
            <description>Participants diagnosed with PsA in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
          <group group_id="O3">
            <title>Participants With AS</title>
            <description>Participants diagnosed with AS in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) Serious AEs (SAEs), and AEs Leading to Study Drug Discontinuation</title>
          <description>An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. An SAE is an AE that results in death, is life-threatening, results in or prolongs hospitalization, results in congenital anomaly, persistent or significant disability/incapacity, spontaneous or elective abortion, or requires intervention to prevent a serious outcome. The protocol required all SAEs to be actively solicited. Non-serious events were not to be actively solicited, and any non-serious AEs were to be collected as spontaneous reports if AbbVie was notified.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2836"/>
                <count group_id="O2" value="1127"/>
                <count group_id="O3" value="1957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE (Includes SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="976"/>
                    <measurement group_id="O2" value="323"/>
                    <measurement group_id="O3" value="493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="560"/>
                    <measurement group_id="O2" value="164"/>
                    <measurement group_id="O3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatal AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE Leading to Study Drug Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="577"/>
                    <measurement group_id="O2" value="171"/>
                    <measurement group_id="O3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to Month 60</time_frame>
      <desc>The protocol required all SAEs to be actively solicited. Non-serious events were not to be actively solicited, and any non-serious AEs were to be collected as spontaneous reports if AbbVie was notified.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>Participants diagnosed with RA, PsA or AS in whom HumiraÂ® (adalimumab) was prescribed within local reimbursement guidelines.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="934" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Antiphospholipid syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Aplasia pure red cell</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Aplastic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lymphocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Neutrophilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Normochromic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Normocytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pseudolymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Retroperitoneal lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Spleen disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arteritis coronary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bundle branch block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardiac fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardiac hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Coronary artery dilatation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dilatation atrial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Heart valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intracardiac mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mitral valve calcification</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Myocardial calcification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pleuropericarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rheumatic heart disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ventricular flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dolichocolon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Thalassaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Trisomy 18</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Truncus arteriosus persistent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Acromegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Addison's disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cushing's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Thyroid cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Toxic nodular goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Altered visual depth perception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arcus lipoides</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Exophthalmos</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Eye inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Eyelids pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Abdominal symptom</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastrointestinal melanosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastrointestinal mucosal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ileal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intra-abdominal fluid collection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lip ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mouth swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pancreatitis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sensitivity of teeth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Small intestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Spigelian hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tongue coated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vasculitis gastrointestinal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Catheter site phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Crepitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Drug effect decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Inflammatory pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Injection site urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Local reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Microlithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Multiple-drug resistance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>No adverse event</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Papillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Paradoxical drug reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="38" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Therapy non-responder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Treatment noncompliance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Unevaluable event</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Biliary cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cryptogenic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Fatty liver alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gallbladder enlargement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatic congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Autoimmune disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Immune system disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Immunodeficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Immunosuppression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arthritis salmonella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bursitis infective staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cranial nerve infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cystitis klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Enterobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Escherichia coli</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatitis B reactivation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Legionella infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Leishmaniasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Meningitis herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nocardiosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ovarian abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pathogen resistance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pelvic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pericarditis tuberculous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="67" subjects_affected="65" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Post procedural pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Proteus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Purulent discharge</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Septic arthritis staphylococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Serratia infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tick-borne viral encephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Toxic shock syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Toxoplasmosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tuberculosis gastrointestinal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Uterine infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vaginal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Drug dose omission</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Eyelid injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="32" subjects_affected="31" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Foetal exposure during pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastroparesis postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ilium fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Kidney rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Post procedural fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Synovial rupture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Traumatic lung injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vaccination complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Albumin globulin ratio increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Alpha 2 globulin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Angiogram peripheral abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Anti-cyclic citrullinated peptide antibody</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Antibody test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Antinuclear antibody positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Biopsy breast abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Biopsy skin abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood creatinine decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood culture positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood immunoglobulin M increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood prolactin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Body temperature decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bronchoscopy abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>C-reactive protein abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Carcinoembryonic antigen increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cardiac murmur functional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Chest X-ray abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Colonoscopy abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Computerised tomogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Double stranded DNA antibody positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Drug level increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ejection fraction abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Q wave abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Electrocardiogram repolarisation abnormality</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus antibody positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Exercise electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Heart sounds abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Immunology test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Inflammatory marker increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>International normalised ratio abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lipids abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lymphocyte count abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nuclear magnetic resonance imaging abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pulse abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pulse absent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rheumatoid factor increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sleep study</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sputum abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Synovial fluid analysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Total lung capacity abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Transaminases abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ultrasound Doppler abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Urine analysis abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Venous pressure jugular increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cell death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Central obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Fluid intake reduced</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hyperinsulinaemic hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hyposideraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Increased insulin requirement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Insulin-requiring type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Metabolic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ankylosing spondylitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Back disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bone disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bone erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bone lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Calcification of muscle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Eosinophilic fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Fracture nonunion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Inguinal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intervertebral disc compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intervertebral disc space narrowing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Joint destruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Knee deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Kyphosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lupus-like syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Muscle necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Osteoporosis postmenopausal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Osteosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Polychondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rheumatic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rheumatoid nodule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Still's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tendon calcification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tendon pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vertebral lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Anaplastic large cell lymphoma T- and null-cell types recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Angioimmunoblastic T-cell lymphoma refractory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Benign hydatidiform mole</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of adrenal gland</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Benign pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma stage I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bronchial neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Chronic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cystadenocarcinoma ovary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Endometrial cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Extranodal marginal zone B-cell lymphoma (MALT type)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Follicle centre lymphoma, follicular grade I, II, III</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Follicular thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Large cell lung cancer stage III</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lentigo maligna</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Linitis plastica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lobular breast carcinoma in situ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Medullary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mesenteric neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Metastases to adrenals</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Metastases to vagina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Paraproteinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rectal cancer stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Thymoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Thyroid cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tumour invasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Uterine neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Waldenstrom's macroglobulinaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute disseminated encephalomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Anosognosia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Apraxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Axonal neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Brain compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Carotid artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cerebral disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Demyelination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dysstasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Encephalitis autoimmune</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haemorrhagic transformation stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Locked-in syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Meningoradiculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Micrographia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Neurodegenerative disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Peripheral sensorimotor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Radicular pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vasculitis cerebral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Device loosening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Affect lability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bruxism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Psychiatric decompensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bladder disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bladder irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cystitis interstitial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diabetic end stage renal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypertensive nephropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nephroangiosclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Renal atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired hydrocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Breast hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Epididymal cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pelvic fluid collection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pelvic haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Apnoeic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bronchopneumopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Chronic respiratory disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Increased bronchial secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nasal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nasal septum disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Obliterative bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Painful respiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pharyngeal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pharyngeal ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pleural disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pulmonary granuloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pulmonary hilum mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Respiratory tract irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Snoring</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acanthosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dermatitis psoriasiform</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Dyshidrotic eczema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Excessive skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Generalised erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Henoch-Schonlein purpura</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nail dystrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nail toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Parakeratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pustular psoriasis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Scar pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Skin dystrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Skin plaque</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Toxic epidermal necrolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bedridden</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Impaired driving ability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Impaired work ability</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Loss of personal independence in daily activities</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Poor personal hygiene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arterial catheterisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arterial stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arthrodesis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bladder operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bone debridement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Breast prosthesis removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Bunion operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Caesarean section</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Corneal transplant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Debridement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Elbow operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Foot operation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intervertebral disc operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Joint arthroplasty</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Joint stabilisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mammoplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Meniscus removal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Metabolic surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Metatarsal excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Nasal operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Peripheral nerve decompression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Peripheral nerve operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Plastic surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Prosthesis implantation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Salpingo-oophorectomy unilateral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Shoulder arthroplasty</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Shoulder operation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Spinal operation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Steroid therapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Suture insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Tendon operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Toe operation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Urinary tract operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Varicose vein operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vascular operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vascular stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Wound drainage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Aneurysm ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Aortitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Arteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Capillary leak syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vascular occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vasculitis necrotising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Vein disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
              <event>
                <sub_title>Venous aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5920"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

